Our product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory medicine, neurology and gastroenterology. We focus on niche generics, transdermal patches, narcotics, controlled release, and first to file and first to market products.
Please note: if you are not located in the United States go to our Worldwide offices for information about products and services in your area.
Alvogen’s sister company, Alvotech, is a uniquely positioned biopharmaceutical business that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing.
Alvogen global operations includes five manufacturing facilities in the U.S., Romania, South-Korea and Taiwan. Capabilities include finished dosage form manufacturing including solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables.
Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information over the lifecycle of each product.
Alvogen has commercial operations in more than 30 countries around the world, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania. Connect directly with our local temas for more information on products, business opportunities and more.
Alvogen has commercial operations in 35 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.